SBRT for Oligoprogressive NSCLC After Treatment With PD-1 Immune Checkpoint Inhibitors
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Despite the impressive response rate to PD-1 immune checkpoint inhibitors, resistance
inevitably develops in most patients. Stereotactic body radiation therapy (SBRT) plays a
growing role in the management of oligometastatic disease. This study aims to evaluate the
efficacy and safety of SBRT for oligoprogressive NSCLC after treatment with PD-1 inhibitors.